127:@0.890196:0.957873:0.914492:0.957873:0.914492:0.938882:0.890196:0.938882:0.007346:0.008359:0.008591
5:@0.941813:0.435294:0.963291:0.435294:0.963291:0.387816:0.941813:0.387816:0.021478
OPTIMIZING NANOPORE SEQUENCING-BASED DETECTION OF STRUCTURAL VARIANTS ENABLES:@0.340931:0.057372:0.882352:0.057372:0.882352:0.040253:0.340931:0.040253:0.008442:0.007975:0.006387:0.003511:0.011112:0.003511:0.006630:0.003511:0.008759:0.008404:0.002988:0.008759:0.007919:0.008759:0.008442:0.008050:0.008442:0.008423:0.006985:0.002988:0.007807:0.006985:0.008442:0.008367:0.006985:0.008759:0.008255:0.003511:0.008759:0.008404:0.005155:0.008121:0.007713:0.007807:0.006985:0.008423:0.002988:0.008423:0.006985:0.006387:0.006985:0.008178:0.006387:0.003511:0.008442:0.008759:0.002988:0.008442:0.006593:0.002988:0.007732:0.006387:0.008367:0.008367:0.008180:0.006387:0.008367:0.008423:0.007919:0.006292:0.002801:0.006966:0.007919:0.008423:0.003511:0.007919:0.008759:0.006313:0.007807:0.002988:0.006985:0.008759:0.007919:0.008236:0.006481:0.006871:0.007807
INDIVIDUALIZED CIRCULATING TUMOR DNA-BASED DISEASE MONITORING IN CANCER PATIENTS:@0.337347:0.073247:0.882352:0.073247:0.882352:0.056128:0.337347:0.056128:0.003511:0.008759:0.008423:0.003511:0.007620:0.003511:0.008423:0.008253:0.007919:0.006481:0.003511:0.006630:0.006985:0.008423:0.002988:0.008255:0.003511:0.008309:0.008255:0.008367:0.006481:0.007097:0.006387:0.003511:0.008759:0.008404:0.002988:0.006387:0.008367:0.011112:0.008442:0.008423:0.002988:0.008423:0.008759:0.007543:0.005155:0.008124:0.007713:0.007807:0.006985:0.008423:0.002988:0.008423:0.003511:0.007807:0.006985:0.007713:0.007807:0.006985:0.002988:0.011112:0.008442:0.008759:0.003511:0.006311:0.008442:0.008423:0.003511:0.008759:0.008404:0.002988:0.003511:0.008759:0.002988:0.008178:0.007919:0.008759:0.008255:0.006985:0.008423:0.002988:0.007581:0.007099:0.006387:0.003511:0.006985:0.008759:0.006311:0.007807
SV-A at baseline:@0.747040:0.447135:0.838003:0.447135:0.838003:0.435651:0.747040:0.435651:0.006726:0.007428:0.004186:0.008351:0.002895:0.006576:0.004513:0.002895:0.007764:0.006576:0.005401:0.006835:0.003216:0.003189:0.007572:0.006842
SV-A at progression:@0.747040:0.461954:0.858046:0.461954:0.858046:0.450470:0.747040:0.450470:0.006732:0.007428:0.004192:0.008358:0.002895:0.006582:0.004520:0.002895:0.007770:0.004328:0.007497:0.007550:0.004328:0.006842:0.005408:0.005408:0.003196:0.007497:0.007579
SV-B at baseline:@0.747040:0.476763:0.837128:0.476763:0.837128:0.465279:0.747040:0.465279:0.006732:0.007426:0.004192:0.007402:0.002895:0.006582:0.004520:0.002895:0.007770:0.006582:0.005408:0.006842:0.003223:0.003196:0.007579:0.006842
SV-B at progression:@0.747040:0.491582:0.857096:0.491582:0.857096:0.480098:0.747040:0.480098:0.006732:0.007428:0.004192:0.007402:0.002895:0.006582:0.004520:0.002895:0.007770:0.004330:0.007497:0.007550:0.004330:0.006842:0.005408:0.005408:0.003196:0.007497:0.007579
Pros1:@0.201798:0.491584:0.233084:0.491584:0.233084:0.480100:0.201798:0.480100:0.007045:0.004330:0.007497:0.005408:0.007006
Pros4:@0.254015:0.491584:0.285302:0.491584:0.285302:0.480100:0.254015:0.480100:0.007045:0.004330:0.007497:0.005408:0.007006
Pros5:@0.306233:0.491584:0.337519:0.491584:0.337519:0.480100:0.306233:0.480100:0.007045:0.004330:0.007497:0.005408:0.007006
Pros6:@0.358447:0.491584:0.389734:0.491584:0.389734:0.480100:0.358447:0.480100:0.007045:0.004330:0.007497:0.005408:0.007006
100:@0.169585:0.384356:0.187100:0.384356:0.187100:0.374786:0.169585:0.374786:0.005838:0.005838:0.005838
10:@0.175332:0.407805:0.187008:0.407805:0.187008:0.398234:0.175332:0.398234:0.005838:0.005838
1:@0.181079:0.432121:0.186917:0.432121:0.186917:0.422550:0.181079:0.422550:0.005838
0.1:@0.173011:0.456437:0.187043:0.456437:0.187043:0.446866:0.173011:0.446866:0.005838:0.002356:0.005838
0.01:@0.167264:0.480753:0.187134:0.480753:0.187134:0.471182:0.167264:0.471182:0.005838:0.002356:0.005838:0.005838
VAF (%) :@0.174606:0.447208:0.174606:0.414875:0.158192:0.414875:0.158192:0.447208:0.006759:-0.612564:0.000000:0.000000:0.000000:0.000000:0.000000:0.651452
10000:@0.467367:0.382412:0.496557:0.382412:0.496557:0.372842:0.467367:0.372842:0.005838:0.005838:0.005838:0.005838:0.005838
1000:@0.473114:0.406728:0.496466:0.406728:0.496466:0.397158:0.473114:0.397158:0.005838:0.005838:0.005838:0.005838
Pros1:@0.509730:0.490907:0.541016:0.490907:0.541016:0.479423:0.509730:0.479423:0.007047:0.004328:0.007497:0.005408:0.007006
Pros4:@0.563192:0.490907:0.594478:0.490907:0.594478:0.479423:0.563192:0.479423:0.007048:0.004328:0.007497:0.005408:0.007006
Pros5:@0.614164:0.490907:0.645450:0.490907:0.645450:0.479423:0.614164:0.479423:0.007048:0.004328:0.007497:0.005408:0.007006
Pros6:@0.666378:0.490907:0.697665:0.490907:0.697665:0.479423:0.666378:0.479423:0.007048:0.004328:0.007497:0.005408:0.007006
100:@0.476375:0.431203:0.493889:0.431203:0.493889:0.421633:0.476375:0.421633:0.005838:0.005838:0.005838
1:@0.487869:0.478968:0.493707:0.478968:0.493707:0.469397:0.487869:0.469397:0.005838
10:@0.482122:0.454650:0.493798:0.454650:0.493798:0.445079:0.482122:0.445079:0.005838:0.005838
Mutant molecules/ml plasma:@0.459314:0.486351:0.459314:0.370342:0.442900:0.370342:0.442900:0.486351:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.163778
C:@0.158688:0.361604:0.166608:0.361604:0.166608:0.350120:0.158688:0.350120:0.007921
D:@0.443393:0.361604:0.452488:0.361604:0.452488:0.350120:0.443393:0.350120:0.009095
Mutant Rev:@0.798182:0.204100:0.863554:0.204100:0.863554:0.192615:0.798182:0.192615:0.010993:0.007538:0.004534:0.006596:0.007525:0.004522:0.002880:0.007361:0.006856:0.006569
A:@0.159646:0.152817:0.168003:0.152817:0.168003:0.141332:0.159646:0.141332:0.008358
Somatic SVs identified by SHARC:@0.225906:0.169709:0.411112:0.169709:0.411112:0.158224:0.225906:0.158224:0.006814:0.007497:0.011389:0.006582:0.004520:0.003196:0.006118:0.002895:0.006732:0.007279:0.005408:0.002895:0.003196:0.007702:0.006842:0.007579:0.004520:0.003196:0.003571:0.003571:0.006842:0.007702:0.002895:0.007675:0.006432:0.002895:0.006732:0.008904:0.008358:0.007347:0.007921
Selection of two SVs based on qPCR results:@0.205749:0.200292:0.448638:0.200292:0.448638:0.188808:0.205749:0.188808:0.006814:0.006842:0.003223:0.006842:0.006294:0.004520:0.003196:0.007497:0.007579:0.002895:0.007497:0.003988:0.002895:0.004643:0.009915:0.007497:0.002895:0.006732:0.007279:0.005408:0.002895:0.007770:0.006582:0.005408:0.006842:0.007702:0.002895:0.007497:0.007579:0.002895:0.007688:0.007265:0.007921:0.007347:0.002895:0.004329:0.006842:0.005408:0.007525:0.003223:0.004520:0.005408
WT primer and probe design for dPCR:@0.221085:0.231659:0.435734:0.231659:0.435734:0.220175:0.221085:0.220175:0.012004:0.006787:0.002895:0.007770:0.004466:0.003196:0.011389:0.006842:0.004466:0.002895:0.006582:0.007579:0.007702:0.002895:0.007770:0.004329:0.007497:0.007770:0.006842:0.002895:0.007702:0.006842:0.005408:0.003196:0.007552:0.007579:0.002895:0.003810:0.007497:0.004466:0.002895:0.007702:0.007265:0.007921:0.007347
Mutant Fwd:@0.557577:0.171866:0.626142:0.171866:0.626142:0.160382:0.557577:0.160382:0.010993:0.007538:0.004534:0.006596:0.007525:0.004520:0.002880:0.006364:0.009913:0.007702
WT downstream Fwd:@0.555292:0.299429:0.675658:0.299429:0.675658:0.287944:0.555292:0.287944:0.012005:0.006787:0.002895:0.007702:0.007402:0.010051:0.007579:0.005408:0.004520:0.004326:0.006842:0.006582:0.011389:0.002895:0.006364:0.009916:0.007702
WT downstream Rev:@0.743953:0.332535:0.861096:0.332535:0.861096:0.321050:0.743953:0.321050:0.012005:0.006787:0.002895:0.007702:0.007402:0.010051:0.007579:0.005408:0.004520:0.004328:0.006842:0.006582:0.011389:0.002895:0.007347:0.006842:0.006569
WT upstream Fwd:@0.556061:0.235647:0.658990:0.235647:0.658990:0.224162:0.556061:0.224162:0.012005:0.006787:0.002895:0.007525:0.007770:0.005408:0.004520:0.004328:0.006842:0.006582:0.011389:0.002895:0.006364:0.009916:0.007702
WT upstream Rev:@0.762202:0.268753:0.861906:0.268753:0.861906:0.257268:0.762202:0.257268:0.012005:0.006787:0.002895:0.007525:0.007770:0.005408:0.004520:0.004328:0.006842:0.006582:0.011389:0.002895:0.007347:0.006842:0.006569
Mutant probe:@0.708603:0.170634:0.787411:0.170634:0.787411:0.159149:0.708603:0.159149:0.010980:0.007525:0.004520:0.006582:0.007579:0.004520:0.002895:0.007770:0.004328:0.007497:0.007770:0.006842
WT upstream probe:@0.707087:0.236521:0.820244:0.236521:0.820244:0.225036:0.707087:0.225036:0.012005:0.006787:0.002895:0.007525:0.007770:0.005408:0.004520:0.004328:0.006842:0.006582:0.011389:0.002895:0.007770:0.004330:0.007497:0.007770:0.006842
WT downstream probe:@0.707906:0.297306:0.838502:0.297306:0.838502:0.285822:0.707906:0.285822:0.012005:0.006787:0.002895:0.007702:0.007402:0.010051:0.007579:0.005408:0.004520:0.004328:0.006842:0.006582:0.011389:0.002895:0.007770:0.004330:0.007497:0.007770:0.006842
B:@0.550641:0.152815:0.558043:0.152815:0.558043:0.141330:0.550641:0.141330:0.007402
Pre-amplification and dPCR on  two cfDNA samples:@0.185609:0.260039:0.475858:0.260039:0.475858:0.248555:0.185609:0.248555:0.007047:0.004330:0.007224:0.004192:0.006582:0.011389:0.007770:0.003223:0.003196:0.003571:0.003571:0.006118:0.006582:0.004520:0.003196:0.007497:0.007579:0.002895:0.006582:0.007579:0.007702:0.002895:0.007702:0.007265:0.007921:0.007347:0.002895:0.007497:0.007579:0.002895:0.002895:0.004642:0.009915:0.007497:0.002895:0.006118:0.003988:0.009095:0.008986:0.008358:0.002895:0.005408:0.006582:0.011389:0.007770:0.003223:0.006842:0.005408
(baseline and progression):@0.255597:0.271505:0.405852:0.271505:0.405852:0.260020:0.255597:0.260020:0.003878:0.007770:0.006582:0.005408:0.006842:0.003223:0.003196:0.007579:0.006842:0.002895:0.006582:0.007579:0.007702:0.002895:0.007770:0.004324:0.007497:0.007553:0.004329:0.006842:0.005408:0.005408:0.003196:0.007497:0.007579:0.003878
dPCR on stock of longitudinal cfDNA samples:@0.189664:0.299461:0.446232:0.299461:0.446232:0.287976:0.189664:0.287976:0.007702:0.007265:0.007921:0.007347:0.002895:0.007497:0.007579:0.002895:0.005408:0.004435:0.007497:0.006118:0.006405:0.002895:0.007497:0.003988:0.002895:0.003223:0.007497:0.007579:0.007549:0.003196:0.004520:0.007525:0.007702:0.003196:0.007579:0.006582:0.003223:0.002895:0.006118:0.003988:0.009095:0.008986:0.008358:0.002895:0.005408:0.006582:0.011389:0.007770:0.003223:0.006842:0.005408
Calculation of VAF and mutant molecules/ml plasma:@0.167601:0.329793:0.463982:0.329793:0.463982:0.318308:0.167601:0.318308:0.007825:0.006582:0.003223:0.006118:0.007525:0.003223:0.006582:0.004520:0.003196:0.007497:0.007579:0.002895:0.007497:0.003988:0.002403:0.006842:0.008358:0.006650:0.002895:0.006582:0.007579:0.007702:0.002895:0.011389:0.007525:0.004520:0.006582:0.007579:0.004520:0.002895:0.011389:0.007497:0.003223:0.006842:0.006118:0.007525:0.003223:0.006842:0.005408:0.004684:0.011389:0.003223:0.002895:0.007770:0.003223:0.006582:0.005408:0.011389:0.006582
Week:@0.315608:0.679931:0.346801:0.679931:0.346801:0.668447:0.315608:0.668447:0.011104:0.006842:0.006842:0.006405
E:@0.158685:0.520029:0.165404:0.520029:0.165404:0.508545:0.158685:0.508545:0.006719
VAF (%) :@0.174606:0.610578:0.174606:0.578246:0.158192:0.578246:0.158192:0.610578:0.006758:-0.381924:0.000000:0.000000:0.000000:0.000000:0.000000:0.420811
100:@0.173628:0.535101:0.194645:0.535101:0.194645:0.523617:0.173628:0.523617:0.007006:0.007006:0.007006
10:@0.179377:0.595399:0.193388:0.595399:0.193388:0.583914:0.179377:0.583914:0.007006:0.007006
0:@0.185126:0.660655:0.192132:0.660655:0.192132:0.649171:0.185126:0.649171:0.007006
0:@0.195819:0.668060:0.202825:0.668060:0.202825:0.656576:0.195819:0.656576:0.007006
10:@0.246719:0.668060:0.260730:0.668060:0.260730:0.656576:0.246719:0.656576:0.007006:0.007006
20:@0.300437:0.668060:0.314448:0.668060:0.314448:0.656576:0.300437:0.656576:0.007006:0.007006
30:@0.354114:0.668060:0.368125:0.668060:0.368125:0.656576:0.354114:0.656576:0.007006:0.007006
40:@0.407336:0.668060:0.421347:0.668060:0.421347:0.656576:0.407336:0.656576:0.007006:0.007006
50:@0.461189:0.668060:0.475201:0.668060:0.475201:0.656576:0.461189:0.656576:0.007006:0.007006
10:@0.474269:0.660522:0.488281:0.660522:0.488281:0.649037:0.474269:0.649037:0.007006:0.007006
100:@0.474269:0.597988:0.495286:0.597988:0.495286:0.586504:0.474269:0.586504:0.007006:0.007006:0.007006
1000:@0.474269:0.535101:0.502292:0.535101:0.502292:0.523617:0.474269:0.523617:0.007006:0.007006:0.007006:0.007006
Cabazitaxel:@0.206921:0.538225:0.272007:0.538225:0.272007:0.526741:0.206921:0.526741:0.007825:0.006582:0.007770:0.006582:0.005845:0.003196:0.004520:0.006582:0.006118:0.006842:0.003223
PD:@0.411328:0.529292:0.427688:0.529292:0.427688:0.517807:0.411328:0.517807:0.007265:0.009095
Pros1:@0.315639:0.520034:0.346925:0.520034:0.346925:0.508549:0.315639:0.508549:0.007047:0.004329:0.007497:0.005408:0.007006
U/L or ug/L :@0.497356:0.567285:0.497356:0.614092:0.513770:0.614092:0.513770:0.567285:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.047455
SV-A:@0.572513:0.592649:0.599168:0.592649:0.599168:0.581164:0.572513:0.581164:0.006705:0.007428:0.004165:0.008358
SV-B :@0.572513:0.607468:0.601162:0.607468:0.601162:0.595983:0.572513:0.595983:0.006732:0.007428:0.004192:0.007402:0.002895
PSA:@0.572513:0.622286:0.594868:0.622286:0.594868:0.610802:0.572513:0.610802:0.007265:0.006732:0.008358
ALP:@0.572513:0.637105:0.594581:0.637105:0.594581:0.625621:0.572513:0.625621:0.008358:0.006446:0.007265
Treatment :@0.572528:0.649614:0.634104:0.649614:0.634104:0.638129:0.572528:0.638129:0.006174:0.004328:0.006828:0.006569:0.004507:0.011376:0.006828:0.007566:0.004507:0.002895
Figure 4: dPCR-based quantification of SVs in blood. (A):@0.147059:0.727665:0.555304:0.727665:0.555304:0.710374:0.147059:0.710374:0.009488:0.005080:0.008797:0.009730:0.006761:0.007751:0.002914:0.008927:0.004445:0.002914:0.009712:0.010571:0.012084:0.010739:0.005902:0.009581:0.008068:0.006742:0.007954:0.009712:0.002914:0.009226:0.009805:0.007900:0.009861:0.005752:0.005080:0.004949:0.005024:0.007695:0.007807:0.005752:0.005155:0.009264:0.009955:0.002914:0.009264:0.005678:0.002914:0.008666:0.012102:0.006574:0.002914:0.005080:0.009955:0.002914:0.009432:0.004854:0.009618:0.009618:0.009562:0.004445:0.002914:0.006238:0.012345:0.006238
 Schematic overview of quantification of tumor-:@0.555314:0.727665:0.882395:0.727665:0.882395:0.710996:0.555314:0.710996:0.002988:0.008666:0.007172:0.009245:0.007396:0.014381:0.007209:0.005267:0.004538:0.007359:0.002988:0.008890:0.007881:0.007396:0.006873:0.008050:0.004538:0.007637:0.012046:0.002988:0.008871:0.005080:0.002988:0.008759:0.009488:0.007433:0.009320:0.005267:0.004594:0.004650:0.004594:0.007452:0.007209:0.005267:0.004538:0.008871:0.009618:0.002988:0.008871:0.005080:0.002988:0.005043:0.009338:0.014308:0.008871:0.005920:0.006163
specific SVs, identified by SHARC, in cfDNA from blood by using qPCR and dPCR. :@0.147059:0.742217:0.731778:0.742217:0.731778:0.725548:0.147059:0.725548:0.006145:0.009413:0.007452:0.007359:0.004594:0.004650:0.004594:0.007359:0.003642:0.008274:0.012345:0.006275:0.003679:0.003642:0.004538:0.009264:0.007396:0.009320:0.005267:0.004594:0.004650:0.004593:0.007452:0.009320:0.003642:0.008871:0.007956:0.003642:0.007994:0.013148:0.012214:0.010888:0.012009:0.003679:0.003642:0.004594:0.009618:0.003642:0.007359:0.005080:0.012905:0.012607:0.012214:0.003642:0.005248:0.006089:0.008871:0.014437:0.003642:0.008927:0.004240:0.009224:0.009226:0.009320:0.003642:0.008869:0.007956:0.003642:0.009338:0.006219:0.004594:0.009376:0.008068:0.003642:0.009021:0.009955:0.012009:0.010944:0.003642:0.007433:0.009490:0.009320:0.003642:0.009320:0.009955:0.012009:0.011206:0.003679:0.003362
(B) :@0.732006:0.742217:0.759030:0.742217:0.759030:0.724926:0.732006:0.724926:0.006238:0.011262:0.006238:0.003287
Primer and probe :@0.759301:0.742217:0.885722:0.742217:0.885722:0.725548:0.759301:0.725548:0.009749:0.006387:0.004594:0.014306:0.007396:0.006387:0.003642:0.007433:0.009488:0.009320:0.003642:0.009058:0.006089:0.008965:0.009207:0.007396:0.003362
design for dPCR. The wild-type upstream and wild-type downstream allele share each one primer with the :@0.147059:0.756769:0.885673:0.756769:0.885673:0.740100:0.147059:0.740100:0.009264:0.007396:0.006219:0.004594:0.008068:0.009618:0.003735:0.004931:0.008871:0.006387:0.003735:0.009320:0.009955:0.012009:0.011204:0.003679:0.003735:0.009385:0.009254:0.007396:0.003735:0.012046:0.004706:0.004240:0.009320:0.006163:0.005267:0.007956:0.009413:0.007396:0.003735:0.009058:0.009151:0.006145:0.005267:0.006089:0.007601:0.007433:0.014437:0.003735:0.007435:0.009488:0.009320:0.003735:0.012046:0.004706:0.004240:0.009320:0.006163:0.005267:0.007956:0.009413:0.007396:0.003735:0.009264:0.008890:0.012046:0.009506:0.006145:0.005267:0.006089:0.007601:0.007433:0.014437:0.003735:0.007695:0.004408:0.004240:0.007321:0.004240:0.007396:0.003735:0.006182:0.009320:0.007433:0.006089:0.007396:0.003735:0.007599:0.007601:0.007172:0.009376:0.003735:0.008871:0.009488:0.007396:0.003735:0.009058:0.006387:0.004594:0.014306:0.007396:0.006387:0.003735:0.012046:0.004314:0.005416:0.009376:0.003735:0.005416:0.009245:0.007396:0.003362
mutant allele. Three probes with different fluorescents were designed to specifically detect the mutant allele :@0.147059:0.771321:0.885802:0.771321:0.885802:0.754652:0.147059:0.754652:0.014138:0.009058:0.005360:0.007433:0.009320:0.005267:0.003717:0.007695:0.004406:0.004241:0.007321:0.004240:0.007153:0.003679:0.003717:0.009385:0.009385:0.006089:0.007452:0.007396:0.003717:0.009058:0.006089:0.008965:0.009207:0.007396:0.006275:0.003717:0.012046:0.004314:0.005416:0.009376:0.003717:0.009320:0.004594:0.004884:0.004733:0.007396:0.006089:0.007396:0.009320:0.005267:0.003717:0.004613:0.004333:0.009282:0.008871:0.006089:0.007396:0.006443:0.007359:0.007396:0.009320:0.005267:0.006275:0.003717:0.011878:0.007396:0.006089:0.007396:0.003717:0.009264:0.007396:0.006221:0.004594:0.008068:0.009486:0.007452:0.009320:0.003717:0.005080:0.009039:0.003717:0.006145:0.009413:0.007450:0.007359:0.004594:0.004650:0.004594:0.007452:0.007695:0.004408:0.004240:0.007956:0.003717:0.009265:0.007469:0.005082:0.007450:0.007452:0.005267:0.003717:0.005416:0.009245:0.007396:0.003717:0.014138:0.009058:0.005360:0.007433:0.009320:0.005267:0.003717:0.007695:0.004408:0.004240:0.007321:0.004240:0.007396:0.003362
or one of the wild-type alleles. :@0.147059:0.785873:0.362921:0.785873:0.362921:0.769204:0.147059:0.769204:0.008871:0.006387:0.004744:0.008871:0.009488:0.007396:0.004744:0.008871:0.005080:0.004744:0.005416:0.009247:0.007396:0.004744:0.012046:0.004705:0.004240:0.009320:0.006163:0.005267:0.007956:0.009413:0.007396:0.004744:0.007695:0.004408:0.004240:0.007321:0.004240:0.007396:0.006275:0.003679:0.003362
(C) :@0.364315:0.785873:0.392162:0.785873:0.392162:0.768582:0.364315:0.768582:0.006238:0.012084:0.006238:0.003287
Detection of two tumor-specific SVs in cfDNA from blood from four :@0.393515:0.785873:0.885692:0.785873:0.885692:0.769204:0.393515:0.769204:0.013279:0.007471:0.005080:0.007452:0.007452:0.005267:0.004538:0.008871:0.009618:0.004744:0.008871:0.005080:0.004744:0.005267:0.011878:0.009039:0.004744:0.005043:0.009338:0.014306:0.008871:0.005920:0.006163:0.006145:0.009413:0.007452:0.007359:0.004594:0.004650:0.004594:0.007359:0.004744:0.008274:0.012345:0.006275:0.004744:0.004594:0.009618:0.004744:0.007359:0.005080:0.012905:0.012607:0.012214:0.004744:0.005246:0.006089:0.008871:0.014437:0.004744:0.008925:0.004241:0.009224:0.009226:0.009320:0.004744:0.005248:0.006089:0.008871:0.014437:0.004744:0.004931:0.008853:0.009338:0.006387:0.003362
patients with prostate cancer at baseline and at progression of disease with dPCR. Shown are VAF and :@0.147059:0.800425:0.855681:0.800425:0.855681:0.783756:0.147059:0.783756:0.009301:0.007209:0.005267:0.004538:0.007396:0.009320:0.005267:0.006275:0.003922:0.012046:0.004312:0.005416:0.009376:0.003922:0.009058:0.006089:0.008965:0.006145:0.005360:0.007209:0.005080:0.007396:0.003922:0.007450:0.007435:0.009488:0.007359:0.007396:0.006387:0.003922:0.007209:0.005267:0.003922:0.009095:0.007601:0.006443:0.007321:0.004296:0.004594:0.009488:0.007396:0.003922:0.007433:0.009490:0.009320:0.003922:0.007209:0.005267:0.003922:0.009058:0.006089:0.009039:0.008068:0.006089:0.007396:0.006163:0.006219:0.004538:0.008871:0.009618:0.003922:0.008871:0.005080:0.003922:0.009320:0.004594:0.006443:0.007601:0.007601:0.006443:0.007396:0.003922:0.012046:0.004314:0.005416:0.009376:0.003922:0.009320:0.009955:0.012009:0.011206:0.003679:0.003922:0.008031:0.009245:0.008890:0.012046:0.009618:0.003922:0.007433:0.006089:0.007396:0.003922:0.010291:0.012214:0.009226:0.003922:0.007433:0.009488:0.009320:0.003362
(D) :@0.856355:0.800425:0.885640:0.800425:0.885640:0.783135:0.856355:0.783135:0.006238:0.013522:0.006238:0.003287
mutant molecules per mL plasma. :@0.147059:0.814977:0.385819:0.814977:0.385819:0.798308:0.147059:0.798308:0.014138:0.009058:0.005360:0.007433:0.009320:0.005267:0.003717:0.014306:0.008946:0.004240:0.007452:0.007452:0.009450:0.004240:0.007396:0.006275:0.003717:0.009413:0.007396:0.006387:0.003717:0.014437:0.009506:0.003717:0.009133:0.004445:0.007601:0.006219:0.014381:0.007601:0.003679:0.003362
(E):@0.386199:0.814977:0.408853:0.814977:0.408853:0.797687:0.386199:0.797687:0.006238:0.010179:0.006238
 Quantification of SVs in longitudinal cfDNA samples from blood of :@0.408853:0.814977:0.885658:0.814977:0.885658:0.798308:0.408853:0.798308:0.003717:0.013447:0.009488:0.007433:0.009320:0.005267:0.004594:0.004650:0.004594:0.007452:0.007209:0.005267:0.004538:0.008869:0.009618:0.003717:0.008871:0.005080:0.003717:0.008274:0.012345:0.006275:0.003717:0.004594:0.009618:0.003717:0.004240:0.008871:0.009376:0.008068:0.004314:0.005043:0.009282:0.009320:0.004594:0.009562:0.007695:0.004296:0.003717:0.007359:0.005080:0.012904:0.012607:0.012214:0.003717:0.006499:0.007433:0.014138:0.009133:0.004240:0.007396:0.006275:0.003717:0.005248:0.006089:0.008871:0.014437:0.003717:0.008927:0.004240:0.009226:0.009226:0.009320:0.003717:0.008869:0.005080:0.003362
patient Pros1. Graph depicts VAFs of SVs, treatment, laboratory parameters (prostate specific membrane :@0.147059:0.829529:0.885636:0.829529:0.885636:0.812861:0.147059:0.812861:0.009301:0.007209:0.005267:0.004538:0.007396:0.009320:0.005267:0.004800:0.009749:0.006089:0.008965:0.006275:0.008535:0.003679:0.004800:0.012663:0.006462:0.007209:0.009133:0.009376:0.004800:0.009265:0.007469:0.009058:0.004538:0.007452:0.005267:0.006275:0.004800:0.010291:0.012214:0.009226:0.006275:0.004800:0.008871:0.005080:0.004800:0.008274:0.012345:0.006275:0.003679:0.004800:0.005267:0.006089:0.007601:0.007209:0.005267:0.014306:0.007396:0.009320:0.005267:0.003679:0.004800:0.004445:0.007452:0.009206:0.008873:0.006460:0.007209:0.005080:0.008871:0.006873:0.007956:0.004800:0.009301:0.007433:0.006462:0.007433:0.014306:0.007471:0.005080:0.007396:0.006238:0.006275:0.004800:0.005678:0.009058:0.006089:0.008965:0.006145:0.005360:0.007209:0.005080:0.007396:0.004800:0.006145:0.009413:0.007452:0.007359:0.004594:0.004650:0.004594:0.007359:0.004800:0.014306:0.007396:0.014231:0.008853:0.006462:0.007433:0.009488:0.007396:0.003362
antigen (PSA), alkaline phosphatase (ALP) and clinical progression of disease (PD).:@0.147059:0.845698:0.719093:0.845698:0.719093:0.829029:0.147059:0.829029:0.007433:0.009320:0.005267:0.004594:0.007900:0.007396:0.009618:0.003362:0.005678:0.009955:0.008274:0.012214:0.005678:0.003679:0.003362:0.007693:0.004408:0.008685:0.007695:0.004296:0.004594:0.009488:0.007396:0.003362:0.009133:0.009245:0.008965:0.006145:0.009133:0.009320:0.007209:0.005360:0.007601:0.006443:0.007396:0.003362:0.005678:0.012214:0.009506:0.009955:0.005678:0.003362:0.007431:0.009488:0.009320:0.003362:0.007172:0.004296:0.004594:0.009618:0.004538:0.007452:0.007695:0.004296:0.003362:0.009056:0.006089:0.009039:0.008068:0.006089:0.007396:0.006163:0.006219:0.004538:0.008871:0.009618:0.003362:0.008871:0.005080:0.003362:0.009320:0.004594:0.006443:0.007601:0.007601:0.006442:0.007396:0.003362:0.005678:0.009544:0.013204:0.005678:0.003679